RT Journal Article SR Electronic T1 Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.11.21252311 DO 10.1101/2021.03.11.21252311 A1 Michael J. Peluso A1 J. Daniel Kelly A1 Scott Lu A1 Sarah A. Goldberg A1 Michelle C. Davidson A1 Sujata Mathur A1 Matthew S. Durstenfeld A1 Matthew A. Spinelli A1 Rebecca Hoh A1 Viva Tai A1 Emily A. Fehrman A1 Leonel Torres A1 Yanel Hernandez A1 Meghann C. Williams A1 Mireya I. Arreguin A1 Jennifer A. Bautista A1 Lynn H. Ngo A1 Monika Deswal A1 Sadie E. Munter A1 Enrique O. Martinez A1 Khamal A. Anglin A1 Mariela D. Romero A1 Jacqueline Tavs A1 Paulina R. Rugart A1 Jessica Y. Chen A1 Hannah M. Sans A1 Victoria W. Murray A1 Payton K. Ellis A1 Kevin C. Donohue A1 Jonathan A. Massachi A1 Jacob O. Weiss A1 Irum Mehdi A1 Jesus Pineda-Ramirez A1 Alex F. Tang A1 Megan Wenger A1 Melissa Assenzio A1 Yan Yuan A1 Melissa Krone A1 Rachel L. Rutishauser A1 Isabel Rodriguez-Barraquer A1 Bryan Greenhouse A1 John A. Sauceda A1 Monica Gandhi A1 Priscilla Y. Hsue A1 Timothy J. Henrich A1 Steven G. Deeks A1 Jeffrey N. Martin YR 2021 UL http://medrxiv.org/content/early/2021/03/13/2021.03.11.21252311.abstract AB BACKGROUND As the coronavirus disease 2019 (COVID-19) pandemic continues and millions remain vulnerable to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing post-acute sequelae of SARS-CoV-2 infection (PASC).METHODS From April 21 to December 31, 2020, we assembled a cohort of consecutive volunteers who a) had documented history of SARS-CoV-2 RNA-positivity; b) were ≥ 2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were able to travel to our site in San Francisco. Participants learned about the study by being identified on medical center-based registries and being notified or by responding to advertisements. At 4-month intervals, we asked participants about physical symptoms that were new or worse compared to the period prior to COVID-19, mental health symptoms and quality of life. We described 4 time periods: 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral specimens were collected at each visit.RESULTS We have, to date, enrolled 179 adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the acute phase, the most common symptoms were fatigue, fever, myalgia, cough and anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were the most commonly reported symptoms, but a variety of others were endorsed by at least some participants. Some experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with ambulation and performance of usual activities. The median visual analogue scale value rating of general health was lower at 4 and 8 months (80, interquartile range [IQR]: 70-90; and 80, IQR 75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected at nearly 600 participant-visits.CONCLUSION Among a cohort of participants enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with persistent physical symptoms through 8 months following onset of COVID-19 with an impact on self-rated overall health. The presence of participants with and without symptoms and ample biological specimens will facilitate study of PASC pathogenesis. Similar evaluations in a population-representative sample will be needed to estimate the population-level prevalence of PASC.Competing Interest StatementTJH reports grants from Merck and Co., Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work. The other authors report no conflicts.Clinical TrialNCT04362150Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases (NIH/NIAID 3R01AI141003-03S1 [to TJ Henrich], NIH/NIAID R01AI158013 [to M Gandhi and M Spinelli] and by the Zuckerberg San Francisco Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine. MJP is supported on NIH T32 AI60530-12 and by the UCSF Resource Allocation Program. MSD is supported by NIH 5T32HL007731-28. JDK is supported on NIH/NIAID AI135037. IRB acknowledges research funding from the MIDAS Coordination Center COVID-19 Urgent Grant Program (MIDASNI2020-5). BG is supported in part by the Chan Zuckerberg Biohub Investigator Fund. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the UCSF Institutional Review Board in April 2020 (IRB#: 20-30479).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is an ongoing study. Data are available upon request and will be provided at the discretion of the study leadership team.